Table of Contents Author Guidelines Submit a Manuscript
Genetics Research International
Volume 2016, Article ID 3451807, 9 pages
http://dx.doi.org/10.1155/2016/3451807
Review Article

Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy

1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran
2Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran

Received 12 November 2015; Revised 21 January 2016; Accepted 24 January 2016

Academic Editor: Francine Durocher

Copyright © 2016 Farzaneh Rami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. R. Raval, A. B. Sharabi, A. J. Walker, C. G. Drake, and P. Sharma, “Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer,” Journal for ImmunoTherapy of Cancer, vol. 2, article 14, 2014. View at Publisher · View at Google Scholar
  2. G. K. Koski, U. Koldovsky, S. Xu et al., “A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized Anti-HER-2/neu responses in women with early breast cancer,” Journal of Immunotherapy, vol. 35, no. 1, pp. 54–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Meissner, T. E. Reichert, M. Kunkel et al., “Defects in the human leukocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: association with clinical outcome,” Clinical Cancer Research, vol. 11, no. 7, pp. 2552–2560, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. P. Medema, J. De Jong, L. T. C. Peltenburg et al., “Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11515–11520, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Töpfer, S. Kempe, N. Müller et al., “Tumor evasion from T cell surveillance,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 918471, 19 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Bogdahn, P. Hau, G. Stockhammer et al., “Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study,” Neuro-Oncology, vol. 13, no. 1, pp. 132–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. P. Kerkar and N. P. Restifo, “Cellular constituents of immune escape within the tumor microenvironment,” Cancer Research, vol. 72, no. 13, pp. 3125–3130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Dietrich and M. Theobald, “Immunologische tumor therapie,” Der Internist, vol. 56, no. 8, pp. 907–916, 2015. View at Publisher · View at Google Scholar
  9. C. L.-L. Chiang, D. A. Maier, L. E. Kandalaft et al., “Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate,” Journal of Translational Medicine, vol. 9, no. 1, article 198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Korman, K. S. Peggs, and J. P. Allison, “Checkpoint blockade in cancer immunotherapy,” Advances in Immunology, vol. 90, pp. 297–339, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Senju, M. Haruta, Y. Matsunaga et al., “Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells,” STEM CELLS, vol. 27, no. 5, pp. 1021–1031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Patel and S. Yang, “Advances in reprogramming somatic cells to induced pluripotent stem cells,” Stem Cell Reviews and Reports, vol. 6, no. 3, pp. 367–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Senju, Y. Matsunaga, S. Fukushima et al., “Immunotherapy with pluripotent stem cell-derived dendritic cells,” Seminars in Immunopathology, vol. 33, no. 6, pp. 603–612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Eguizabal, O. Zenarruzabeitia, J. Monge et al., “Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective,” Frontiers in Immunology, vol. 5, article 439, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Koba, M. Haruta, Y. Matsunaga et al., “Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models,” PLoS ONE, vol. 8, no. 6, Article ID e67567, 2013. View at Publisher · View at Google Scholar
  16. C.-W. Chang, Y.-S. Lai, L. S. Lamb Jr., and T. M. Townes, “Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells,” PLoS ONE, vol. 9, no. 5, Article ID e97335, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Morishima, K. Watanabe, A. Niwa et al., “Neutrophil differentiation from human-induced pluripotent stem cells,” Journal of Cellular Physiology, vol. 226, no. 5, pp. 1283–1291, 2011. View at Publisher · View at Google Scholar
  18. M. Haruta, Y. Tomita, A. Yuno et al., “TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells,” Gene Therapy, vol. 20, no. 5, pp. 504–513, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Antignano, M. Ibaraki, C. Kim et al., “SHIP is required for dendritic cell maturation,” Journal of Immunology, vol. 184, no. 6, pp. 2805–2813, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ballestrero, D. Boy, E. Moran, G. Cirmena, P. Brossart, and A. Nencioni, “Immunotherapy with dendritic cells for cancer,” Advanced Drug Delivery Reviews, vol. 60, no. 2, pp. 173–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Su, C. Frye, K.-M. Bae, V. Kelley, and J. Vieweg, “Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions,” Clinical Cancer Research, vol. 14, no. 19, pp. 6207–6217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. L. M. Liau, K. L. Black, N. A. Martin et al., “Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report,” Neurosurgical Focus, vol. 9, no. 6, article e8, 2000. View at Google Scholar
  23. M. Tewari, S. Sahai, R. R. Mishra, S. K. Shukla, and H. S. Shukla, “Dendritic cell therapy in advanced gastric cancer: a promising new hope?” Surgical Oncology, vol. 21, no. 3, pp. 164–171, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Iwamoto, T. Ojima, M. Nakamori et al., “Cancer vaccine therapy using genetically modified induced pluripotent stem cell-derived dendritic cells expressing the TAA gene,” Gan to Kagaku Ryōhōsha, vol. 40, no. 12, pp. 1575–1577, 2013. View at Google Scholar
  25. F. J. Hsu, C. Benike, F. Fagnoni et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells,” Nature Medicine, vol. 2, no. 1, pp. 52–58, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. Jakobsen, B. K. Møller, and S. T. Lillevang, “Serum concentration of the growth medium markedly affects monocyte-derived dendritic cells' phenotype, cytokine production profile and capacities to stimulate in MLR,” Scandinavian Journal of Immunology, vol. 60, no. 6, pp. 584–591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Matsunaga, D. Fukuma, S. Hirata et al., “Activation of antigen-specific cytotoxic T lymphocytes by β2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells,” The Journal of Immunology, vol. 181, no. 9, pp. 6635–6643, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Fairchild, F. A. Brook, R. L. Gardner et al., “Directed differentiation of dendritic cells from mouse embryonic stem cells,” Current Biology, vol. 10, no. 23, pp. 1515–1518, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Senju, M. Haruta, K. Matsumura et al., “Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy,” Gene Therapy, vol. 18, no. 9, pp. 874–883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K.-D. Choi, M. A. Vodyanik, and I. I. Slukvin, “Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell–derived linCD34+CD43+CD45+ progenitors,” The Journal of Clinical Investigation, vol. 119, no. 9, pp. 2818–2829, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Q. Zhang, M. Fujino, S. Iwasaki et al., “Generation and characterization of regulatory dendritic cells derived from murine induced pluripotent stem cells,” Scientific Reports, vol. 4, article 3979, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Senju, S. Hirata, Y. Motomura et al., “Pluripotent stem cells as source of dendritic cells for immune therapy,” International Journal of Hematology, vol. 91, no. 3, pp. 392–400, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. T.-J. Huang, “Induced pluripotent stem cells—a new foundation in medicine,” Journal of Experimental and Clinical Medicine, vol. 2, no. 5, pp. 202–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Thurner, I. Haendle, C. Röder et al., “Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma,” The Journal of Experimental Medicine, vol. 190, no. 11, pp. 1669–1678, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Banchereau, A. K. Palucka, M. Dhodapkar et al., “Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine,” Cancer Research, vol. 61, no. 17, pp. 6451–6458, 2001. View at Google Scholar
  36. L. Fong, D. Brockstedt, C. Benike et al., “Dendritic cell-based xenoantigen vaccination for prostate cancer Immunotherapy,” Journal of Immunology, vol. 167, no. 12, pp. 7150–7156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Höltl, C. Zelle-Rieser, H. Gander et al., “Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells,” Clinical Cancer Research, vol. 8, no. 11, pp. 3369–3376, 2002. View at Google Scholar · View at Scopus
  38. S. Baek, C.-S. Kim, S.-B. Kim et al., “Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial,” Journal of Translational Medicine, vol. 9, article 178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Motomura, S. S. Senju, T. Nakatsura et al., “Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10,” Cancer Research, vol. 66, no. 4, pp. 2414–2422, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Schuler, B. Schuler-Thurner, and R. M. Steinman, “The use of dendritic cells in cancer immunotherapy,” Current Opinion in Immunology, vol. 15, no. 2, pp. 138–147, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-Q. Bao, C. Jin, B.-H. Xu, Y.-L. Gu, J.-P. Li, and Xiao-Lu, “Vaccination with apoptosis colorectal cancer cell pulsed autologous dendritic cells in advanced colorectal cancer patients: report from a clinical observation,” African Journal of Biotechnology, vol. 10, no. 12, pp. 2319–2327, 2011. View at Google Scholar · View at Scopus
  42. J. Ananiev, M. V. Gulubova, and I. Manolova, “Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-beta 1 in human gastric cancer,” Hepato-Gastroenterology, vol. 58, no. 110-111, pp. 1834–1840, 2011. View at Google Scholar · View at Scopus
  43. I. Nakano and E. A. Chiocca, “Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma,” World Neurosurgery, vol. 77, no. 5-6, pp. 633–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Kayagaki, N. Yamaguchi, M. Nakayama, E. Hiroshi, K. Okumura, and H. Yagita, “Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs,” Journal of Experimental Medicine, vol. 189, no. 9, pp. 1451–1460, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Lei, R. Haque, X. Xiong, and J. Song, “Directed differentiation of induced pluripotent stem cells towards T lymphocytes,” Journal of Visualized Experiments, vol. 63, Article ID e3986, 2012. View at Google Scholar · View at Scopus
  46. F. Lei, B. Zhao, R. Haque et al., “In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance,” Cancer Research, vol. 71, no. 14, pp. 4742–4747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. I. Rousalova and E. Krepela, “Granzyme B-induced apoptosis in cancer cells and its regulation (review),” International Journal of Oncology, vol. 37, no. 6, pp. 1361–1378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Platzer, M. Stout, and E. Fiebiger, “Antigen cross-presentation of immune complexes,” Frontiers in Immunology, vol. 5, article 140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. S. R. Clarke, “The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity,” Journal of Leukocyte Biology, vol. 67, no. 5, pp. 607–614, 2000. View at Google Scholar
  50. C. Le Page, P. Génin, M. G. Baines, and J. Hiscott, “Interferon activation and innate immunity,” Reviews in Immunogenetics, vol. 2, no. 3, pp. 374–386, 2000. View at Google Scholar · View at Scopus
  51. B. Seliger, F. Ruiz-Cabello, and F. Garrido, “IFN inducibility of major histocompatibility antigens in tumors,” Advances in Cancer Research, vol. 101, pp. 249–276, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Cella, D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber, “Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation,” The Journal of Experimental Medicine, vol. 184, no. 2, pp. 747–752, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Kirkwood, L. H. Butterfield, A. A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone, “Immunotherapy of cancer in 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 5, pp. 309–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Corthay, “Does the immune system naturally protect against cancer?” Frontiers in Immunology, vol. 5, article 197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. T. D. S. Fernandez, C. de Souza Fernandez, and A. L. Mencalha, “Human induced pluripotent stem cells from basic research to potential clinical applications in cancer,” BioMed Research International, vol. 2013, Article ID 430290, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Sachamitr, S. Hackett, and P. J. Fairchild, “Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy,” Frontiers in Immunology, vol. 5, article 176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Vizcardo, K. Masuda, D. Yamada et al., “Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells,” Cell Stem Cell, vol. 12, no. 1, pp. 31–36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. J. G. Crompton, M. Rao, and N. P. Restifo, “Memoirs of a reincarnated T cell,” Cell Stem Cell, vol. 12, no. 1, pp. 6–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. R. N. La Motte-Mohs, E. Herer, and J. C. Zúňiga-Pflücker, “Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro,” Blood, vol. 105, no. 4, pp. 1431–1439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. T. M. Schmitt, R. F. de Pooter, M. A. Gronski, S. K. Cho, P. S. Ohashi, and J. C. Zúñiga-Pflücker, “Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro,” Nature Immunology, vol. 5, no. 4, pp. 410–417, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Lei, R. Haque, L. Weiler, K. E. Vrana, and J. Song, “T lineage differentiation from induced pluripotent stem cells,” Cellular Immunology, vol. 260, no. 1, pp. 1–5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. Y.-H. Loh, S. Agarwal, I.-H. Park et al., “Generation of induced pluripotent stem cells from human blood,” Blood, vol. 113, no. 22, pp. 5476–5479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. Ye, H. Zhan, P. Mali et al., “Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders,” Blood, vol. 114, no. 27, pp. 5473–5480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. M. E. Brown, E. Rondon, D. Rajesh et al., “Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes,” PLoS ONE, vol. 5, no. 6, Article ID e11373, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. Y.-H. Loh, O. Hartung, H. Li et al., “Reprogramming of T cells from human peripheral blood,” Cell Stem Cell, vol. 7, no. 1, pp. 15–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Nishimura, S. Kaneko, A. Kawana-Tachikawa et al., “Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation,” Cell Stem Cell, vol. 12, no. 1, pp. 114–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Hataye, J. J. Moon, A. Khoruts, C. Reilly, and M. K. Jenkins, “Naïve and memory CD4+ T cell survival controlled by clonal abundance,” Science, vol. 312, no. 5770, pp. 114–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. C. S. Hinrichs, Z. A. Borman, L. Gattinoni et al., “Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy,” Blood, vol. 117, no. 3, pp. 808–814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. Y.-I. Seki, J. Yang, M. Okamoto et al., “IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs,” Journal of Immunology, vol. 178, no. 1, pp. 262–270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Siewert, U. Lauer, S. Cording et al., “Experience-driven development: effector/memory-like αE+Foxp3+ regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells,” Journal of Immunology, vol. 180, no. 1, pp. 146–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Stemberger, K. M. Huster, M. Koffler et al., “A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets,” Immunity, vol. 27, no. 6, pp. 985–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. L.-X. Wang and G. E. Plautz, “Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure,” The Journal of Immunology, vol. 184, no. 10, pp. 5612–5618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Wada, S. Kojo, C. Kusama et al., “Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells,” International Immunology, vol. 23, no. 1, pp. 65–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Themeli, C. C. Kloss, G. Ciriello et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nature Biotechnology, vol. 31, no. 10, pp. 928–933, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Ciofani, G. C. Knowles, D. L. Wiest, H. von Boehmer, and J. C. Zúñiga-Pflücker, “Stage-specific and differential notch dependency at the αβ and γδ T lineage bifurcation,” Immunity, vol. 25, no. 1, pp. 105–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. T. M. Schmitt, M. Ciofani, H. T. Petrie, and J. C. Zúñiga-Pflücker, “Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions,” Journal of Experimental Medicine, vol. 200, no. 4, pp. 469–479, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Zhao, Z.-N. Zhang, Z. Rong, and Y. Xu, “Immunogenicity of induced pluripotent stem cells,” Nature, vol. 474, no. 7350, pp. 212–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Araki, M. Uda, Y. Hoki et al., “Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells,” Nature, vol. 494, no. 7435, pp. 100–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Kim, A. Doi, B. Wen et al., “Epigenetic memory in induced pluripotent stem cells,” Nature, vol. 467, no. 7313, pp. 285–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Doi, I.-H. Park, B. Wen et al., “Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts,” Nature Genetics, vol. 41, no. 12, pp. 1350–1353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. J. M. Polo, S. Liu, M. E. Figueroa et al., “Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells,” Nature Biotechnology, vol. 28, no. 8, pp. 848–855, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Lister, M. Pelizzola, Y. S. Kida et al., “Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells,” Nature, vol. 471, no. 7336, pp. 68–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. C. S. Hinrichs, R. Spolski, C. M. Paulos et al., “IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy,” Blood, vol. 111, no. 11, pp. 5326–5333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Moroz, C. Eppolito, Q. Li, J. Tao, C. H. Clegg, and P. A. Shrikant, “IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21,” The Journal of Immunology, vol. 173, no. 2, pp. 900–909, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Neeson, A. Shin, K. M. Tainton et al., “Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype,” Gene Therapy, vol. 17, no. 9, pp. 1105–1116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. K. S. Schluns and L. Lefrançois, “Cytokine control of memory T-cell development and survival,” Nature Reviews Immunology, vol. 3, no. 4, pp. 269–279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Zeng, R. Spolski, S. E. Finkelstein et al., “Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function,” The Journal of Experimental Medicine, vol. 201, no. 1, pp. 139–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Singh, M. J. Figliola, M. J. Dawson et al., “Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies,” Cancer Research, vol. 71, no. 10, pp. 3516–3527, 2011. View at Publisher · View at Google Scholar
  89. L. Zhang, X. Song, Y. Mohri, and L. Qiao, “Role of inflammation and tumor microenvironment in the development of gastrointestinal cancers: what induced pluripotent stem cells can do?” Current Stem Cell Research & Therapy, vol. 10, no. 3, pp. 245–250, 2015. View at Publisher · View at Google Scholar
  90. E. Haga, Y. Endo, M. Haruta et al., “Therapy of peritoneally disseminated colon cancer by TAP-Deficient embryonic stem cell-derived macrophages in allogeneic recipients,” Journal of Immunology, vol. 193, no. 4, pp. 2024–2033, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. A. M. Bock, D. Knorr, and D. S. Kaufman, “Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs),” Journal of Visualized Experiments, no. 74, Article ID e50337, 2013. View at Google Scholar · View at Scopus
  92. A. Larbi, J.-M. Gombert, C. Auvray et al., “The HOXB4 homeoprotein promotes the ex vivo enrichment of functional human embryonic stem cell-derived NK cells,” PLoS ONE, vol. 7, no. 6, Article ID e39514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Merchav, A. Nagler, E. Sahar, and I. Tatarsky, “Production of human pluripotent progenitor cell colony stimulating activity (CFU-GEMMCSA) in patients with myelodysplastic syndromes,” Leukemia Research, vol. 11, no. 3, pp. 273–279, 1987. View at Publisher · View at Google Scholar · View at Scopus
  94. C. E. Lewis and J. W. Pollard, “Distinct role of macrophages in different tumor microenvironments,” Cancer Research, vol. 66, no. 2, pp. 605–612, 2006. View at Publisher · View at Google Scholar · View at Scopus